RD162
RD162, a diarylthiohydantoin, is an orally active non-steroidal antiandrogen (NSAA) . RD162 specifically binds to androgen receptor (AR) . RD162 induces tumor regression in mouse models of castration-resistant human prostate cancer[1].
Product Specifications
CAS Number
915087-27-3
UNSPSC
12352005
Target
Androgen Receptor
Type
Reference compound
Related Pathways
Vitamin D Related/Nuclear Receptor
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/rd162.html
Purity
99.69
Solubility
DMSO : 125 mg/mL (ultrasonic)
Smiles
O=C(NC)C1=CC=C(N(C(N(C2=CC=C(C#N)C(C(F)(F)F)=C2)C3=O)=S)C43CCC4)C=C1F
Molecular Formula
C22H16F4N4O2S
Molecular Weight
476.45
References & Citations
[1]Chris Tran, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009 May 8;324 (5928) :787-90.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS1880004-01 0.01 mg
Human GABR2 full length protein-synthetic nanodisc
Sign In for Pricing
View Details MBS1880004-02 0.05 mg
Human GABR2 full length protein-synthetic nanodisc
Sign In for Pricing
View Details MBS1880004-03 0.1 mg
Human GABR2 full length protein-synthetic nanodisc
Sign In for Pricing
View Details 